Angiex Inc.

Angiex Inc. is a biotechnology company based in the US that specializes in developing innovative therapies targeting solid tumors through its unique Nuclear-Delivered Antibody-Drug Conjugates™ technology. Founded in 2015 and headquartered in Cambridge, US, Angiex Inc. focuses on advancing treatments for solid tumors.

The company was established by individuals with previous experience in the biotechnology sector, although specific founder details are not available. Angiex has engaged in strategic financing rounds, most recently raising USD 31 mn to further its clinical development initiatives. Angiex is focused on the development of first-in-class Nuclear-Delivered Antibody-Drug Conjugates™ (ND-ADCs), particularly targeting solid tumors. Their core product offering, AGX101, is a TM4SF1-directed ADC designed to deliver chemotherapeutic payloads directly to the nucleus of tumor cells and the endothelial cells of tumor blood vessels.

This innovative approach aims to overcome the lethality of cancer by providing safe and effective therapeutics with an exceptional therapeutic margin. Angiex's technology has been designed to address significant unmet medical needs in oncology, particularly for patients with advanced solid tumors. The company primarily targets markets in North America and Europe, focusing on healthcare institutions and oncology specialists as key users of its products. Angiex has recently completed financing totaling USD 31 mn to support the Phase 1 clinical development of AGX101, reflecting its strategic positioning in the biotechnology sector.

Revenue generation for Angiex is expected to occur through partnerships and collaborations with pharmaceutical companies and healthcare providers, which typically involves agreements for clinical trials and potential commercialization post-approval. The company’s flagship product, AGX101, is central to these revenue streams, potentially involving transactional structures that align with clinical development milestones. As the company progresses through clinical trials, it may engage in discussions for licensing agreements or partnerships with larger pharmaceutical firms, further facilitating revenue opportunities aligned with the successful introduction of its ND-ADC products into the market.